Indivior Pharmaceuticals, Inc. INDV Estimated Litigation Liability, Noncurrent
Estimated Litigation Liability, Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LitigationReserveNoncurrent.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's estimated litigation liability, noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's estimated litigation liability, noncurrent?
- Indivior Pharmaceuticals, Inc. (INDV) reported estimated litigation liability, noncurrent of $41M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's estimated litigation liability, noncurrent changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's estimated litigation liability, noncurrent decreased by 86.2% year-over-year, from $297M to $41M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's estimated litigation liability, noncurrent?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's estimated litigation liability, noncurrent has grown at a -61.9% compound annual growth rate (CAGR), from $359M to $52M.